SC 13G/A | 2023-02-14 | BAKER BROS. ADVISORS LP | Mereo Biopharma Group plc | 69,359,359 | 10.0% | EDGAR |
SC 13G/A | 2023-02-14 | Rock Springs Capital Management LP | Mereo Biopharma Group plc | 31,224,485 | 5.3% | EDGAR |
SC 13G/A | 2023-02-14 | Vivo Capital IX, LLC | Mereo Biopharma Group plc | 839,435 | 0.7% | EDGAR |
SC 13G/A | 2023-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Mereo Biopharma Group plc | 36,822,190 | 5.9% | EDGAR |
SC 13D/A | 2022-10-28 | Rubric Capital Management LP | Mereo Biopharma Group plc | 83,780,600 | 13.4% | EDGAR |
SC 13D/A | 2022-09-23 | Rubric Capital Management LP | Mereo Biopharma Group plc | 83,780,600 | 13.4% | EDGAR |
SC 13D/A | 2022-08-24 | Rubric Capital Management LP | Mereo Biopharma Group plc | 83,780,600 | 14.3% | EDGAR |
SC 13D/A | 2022-06-14 | Rubric Capital Management LP | Mereo Biopharma Group plc | 82,272,810 | 14.1% | EDGAR |
SC 13D/A | 2022-06-09 | Rubric Capital Management LP | Mereo Biopharma Group plc | 76,792,625 | 13.1% | EDGAR |
SC 13D | 2022-05-26 | Rubric Capital Management LP | Mereo Biopharma Group plc | 75,000,000 | 12.8% | EDGAR |
SC 13G | 2022-02-15 | Rock Springs Capital Management LP | Mereo Biopharma Group plc | 5,585,621 | 5.1% | EDGAR |
SC 13G/A | 2022-02-14 | Point72 Asset Management, L.P. | Mereo Biopharma Group plc | 10,610,000 | 9.1% | EDGAR |
SC 13G/A | 2022-02-14 | CITADEL ADVISORS LLC | Mereo Biopharma Group plc | - | 3.6% | EDGAR |
SC 13G/A | 2022-02-14 | Rubric Capital Management LP | Mereo Biopharma Group plc | 74,572,235 | 13.7% | EDGAR |
SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Mereo Biopharma Group plc | 64,917,601 | 10.0% | EDGAR |
SC 13G/A | 2022-02-14 | Boxer Capital, LLC | Mereo Biopharma Group plc | 4,082,576 | 3.6% | EDGAR |
SC 13G/A | 2022-02-11 | SUVRETTA CAPITAL MANAGEMENT, LLC | Mereo Biopharma Group plc | 45,710,335 | 8.4% | EDGAR |
SC 13G/A | 2022-02-11 | ORBIMED ADVISORS LLC | Mereo Biopharma Group plc | 3,815,676 | 3.5% | EDGAR |
SC 13G/A | 2022-02-11 | Vivo Capital IX, LLC | Mereo Biopharma Group plc | 2,099,520 | 1.8% | EDGAR |
SC 13G | 2021-12-02 | Rubric Capital Management LP | Mereo Biopharma Group plc | 56,500,000 | 10.4% | EDGAR |